Meritage Weighs Its Options As It Looks Toward Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Meritage Pharma announced Phase II results of its EoE drug, with hopes of being the first to market in the indication.
You may also be interested in...
From Verus to Meritage: A Biotech Prototype for Tough Economic Times
Prolific entrepreneur Cam Garner has a new model for start-ups. Gone are the days of raising huge A rounds to build commercial infrastructure and license in families of products. His two new firms, Meritage and Evoke, are narrowly focused on single assets, in each case a reformulation of an approved drug repositioned in an underserved specialty indication.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.